Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience

Solitary fibrous tumor (SFT) is a mesenchymal neoplasm of fibrous origin. The 2013 WHO classification of soft tissue tumors defines malignant forms as hypercellular, mitotically active (>4 mitosis/10 high-power fields), with cytological atypia, tumor necrosis, and/or infiltrative margins. With an...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2015-10, Vol.10 (10), p.e0140362-e0140362
Main Authors: DeVito, Nicholas, Henderson, Evita, Han, Gang, Reed, Damon, Bui, Marilyn M, Lavey, Robert, Robinson, Lary, Zager, Jonathan S, Gonzalez, Ricardo J, Sondak, Vernon K, Letson, G Douglas, Conley, Anthony
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Benign
Cancer therapies
Care and treatment
Chemotherapy
Diagnosis
Female
Fibrous tissue tumors
Gangrene
Gastrointestinal Neoplasms - epidemiology
Gastrointestinal Neoplasms - pathology
Gastrointestinal Neoplasms - therapy
Gene expression
Growth factors
Histology
Humans
Lungs
Male
Medical diagnosis
Medical prognosis
Mesenchyme
Metastases
Metastasis
Middle Aged
Mitosis
Neck
Neoplasia
Neurosurgery
Oncology
Pathology
Patient outcomes
Patients
Pelvis
Pleura
Radiation
Radiation therapy
Respiratory Tract Neoplasms - epidemiology
Respiratory Tract Neoplasms - pathology
Respiratory Tract Neoplasms - therapy
Review boards
Sarcoma
Social security
Solitary Fibrous Tumors - epidemiology
Solitary Fibrous Tumors - pathology
Solitary Fibrous Tumors - therapy
Statistical analysis
Surgery
Survival
Survival Analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Solitary fibrous tumor (SFT) is a mesenchymal neoplasm of fibrous origin. The 2013 WHO classification of soft tissue tumors defines malignant forms as hypercellular, mitotically active (>4 mitosis/10 high-power fields), with cytological atypia, tumor necrosis, and/or infiltrative margins. With an IRB-approved protocol, we investigated patient records and clinicopathologic data from our Sarcoma Database to describe the clinical characteristics of both benign and malignant SFT. All pathology specimens were reviewed by two pathologists. Descriptive statistics and univariate/multivariate survival analysis were performed. Patient records and Social Security Death Index were used to evaluate vital status. Of 82 patients, 47 (57%) were women and 73 (89%) were Caucasian. Median age was 62 years (range, 20 to 89). Thirty-two (39%) patients succumbed to the disease. Primary tumor site was lung/pleura in 28 (34%), abdomen/pelvis in 23 (28%), extremity in 13 (16%), and head/neck in 9 (11%) patients. Pathology was described as benign in 42 (51%) and malignant in 40 (49%) patients. Compared to benign SFT, malignant histology is associated with larger tumor size, higher mitotic counts, metastatic disease at diagnosis, and greater use of chemotherapy and radiation therapy. Gender, age, and tumor site were not significantly different between benign and malignant subtypes. By univariate analysis, only benign vs. malignant variant and complete resection positively impacted overall survival (P = 0.02 and P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0140362